Cargando…
Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea
This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy. We retrospectively reviewed the medical records of 300 malignant glioma patients treated with temozolomide in two medical institutions in Korea between 2004...
Autores principales: | Bae, So Hyun, Park, Min-Jung, Lee, Min Mi, Kim, Tae Min, Lee, Se-Hoon, Cho, Sung Yun, Kim, Young-Hoon, Kim, Yu Jung, Park, Chul-Kee, Kim, Chae-Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101787/ https://www.ncbi.nlm.nih.gov/pubmed/25045231 http://dx.doi.org/10.3346/jkms.2014.29.7.980 |
Ejemplares similares
-
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
por: Kim, Byung Sup, et al.
Publicado: (2017) -
Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas
por: Yang, Seung-Ho, et al.
Publicado: (2006) -
Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma
por: Cha, Yongjun, et al.
Publicado: (2017) -
Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study)
por: Ahn, Grace S., et al.
Publicado: (2022) -
Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study)
por: Hwang, Kihwan, et al.
Publicado: (2020)